Kornimate/medical-research-clean huggingface dataset:
impact of catheter ablation of ventricular arrhythmias on suboptimal biventricular pacing in cardiac resynchronization therapy

Conditions: Systolic Heart Failure; Ventricular Premature Complexes; Ventricular Tachycardia; Cardiac Resynchronization Therapy; Reduced Biventricular Pacing

Summary: cardiac resynchronization therapy reduces mortality in patients with systolic heart failure and left bundle branch block. reduced biventricular pacing can lead to therapy failure. most effective mortality reduction was seen with a biv pacing above 98%. reduced biv pacing is a common phenomenon with potential impact on crt-response and pts' prognosis. frequent ventricular ectopy may be associated with attenuated benefit from crt. the investigators sought to systematically assess the effect of ventricular arrhythmia treatment on biv pacing.


Eligibility criteria:
inclusion criteria: * reduced biventricular pacing \<98% due to ventricular arrhythmia exclusion criteria: * reduced biventricular pacing \<98% due to other cause * age \<18 * pregnancy
the efficacy of n-acetylcysteine versus placebo for the treatment of metamphetamine withdrawal symptoms

Conditions: Methamphetamine Dependence in Remission

Summary: up to date, no approved medications are available for the treatment of methamphetamine addiction. recently, n-acetylcysteine is recently being studied for methamphetamine withdrawal. n-acetylcysteine, is a drug that has been long used as a mucolytic. recent studies investigate the use of n-acetylcysteine in cocaine and withdrawal symptoms by its effect on restoring glutamate homeostasis in nucleus accumbens. up to date, there has been 2 pilot study investigating the efficacy of n-acetylcysteine for methamphetamine dependence. the present study is aimed to confirm the efficacy and safety of n-acetylcysteine in the treatment of methamphetamine withdrawal symptoms.

methamphetamine is a stimulant commonly abused worldwide. methamphetamine can produce a rapid pleasurable rush caused by release of dopamine, nor-ephinephrine and serotonin. it produces euphoria, a heightened level of alertness and increased level of alertness and increased energy. long-term regular meth use can lead to severe tooth decay, infection, weight loss, malnutrition, kidney damage, liver damage, respiratory issues, paranoia, violent behaviour, psychosis, severe anxiety and depression. studies suggested that withdrawal symptoms in methamphetamine dependent patients were due to the state of hypodopaminergic activities. up to date, no approved medications are available for the treatment of methamphetamine addiction. recently, n-acetylcysteine is recently being studied for methamphetamine withdrawal. n-acetylcysteine, is a drug that has been long used as a mucolytic. up to date, there has been 2 pilot study investigating the efficacy of n-acetylcysteine for methamphetamine dependence. the present study is aimed to confirm the efficacy and safety of n-acetylcysteine in the treatment of methamphetamine withdrawal symptoms.

Eligibility criteria:
inclusion criteria: * men or women, 18 - 60 years old * diagnosed with methamphetamine addiction based on dsm-v criteria, enrolling for methamphetamine withdrawal treatment * agree to participate in the trial by signing informed consent exclusion criteria: * known hypersensitivity to n-acetylcysteine * patients with serious conditions that will not allow protocol compliance or safe participation in the clinical trials. * pregnant or breastfeeding women * history of suicidal thoughts / behaviour * history of n-acetylcysteine treatment * history of asthma and convulsions

Keywords: methamphetamine n-acetylcysteine substance abuse
effects of myofascial induction pressure pain threshold in trigger points of the proximal muscles of gastrocnemius

Conditions: Myofascial Trigger Point; Gastrocnemius Muscle; Manual Therapy; Pain Threshold

Summary: in the present study we will test the effects of myofascial induction technique in the muscles close to the application in the gastrocnemius muscle.

in the present study we will test the effects of myofascial induction technique on nearby muscles. the calf maneuver proposed by pilat for myofascial induction will be applied and the effects on the pain pressure threshold of the trigger points of the flexor digitorum brevis biceps femoris extensor digitorum longus muscles will be observed.

Eligibility criteria:
inclusion criteria: * subjects aged 18-39 years. * healthy subjects with trigger point 1 of the gastrocnemius muscle in both lower limbs. exclusion criteria; * diagnosis of lower limb injury, including any tendinopathy, bursitis, ligamentous involvement and/or fasciitis. * history of lower limb surgery or history of lower limb injury with residual symptoms (pain or sensation of sensation) within the last year. * participants could not have undergone ankle stretching or any other treatment. * diabetes due to possible impaired distal arterial circulation. * foot deformity, cavus and flat feet. * foot deformities such as hammertoes and hallux valgus, * plantar calluses. * dysfunction of the lower extremities or chronic injuries.

Keywords: gastrocnemius muscle range of motion lower limb therapeutics
biventricular pacing in hypertrophic cardiomyopathy after aortic valve replacement

Conditions: Hypertrophic Cardiomyopathy

Summary: biventricular pacing has been shown an improvement of symptoms in patients with heart failure. a temporary pacing is necessary in patients after cardiac procedures. in patients with hypertrophic cardiomyopathy, a single right ventricular pacing can decrease the cardiac output and blood pressure. the investigators propose that biventricular pacing in these patients and conditions results in an improvement of symptoms instead of single right pacing.


Eligibility criteria:
inclusion criteria: * 18 years * hypertrophic cardiomyopathy * aortic valve replacement exclusion criteria: * atrial fibrillation * pericarditis * postoperative low output * preoperative permanent pacemaker placement

Keywords: hypertrophic cardiomyopathy diastolic ventricular interaction biventricular pacemaker cardiac surgery aortic valve replacement
independent use of brain measurement-based rehabilitation system by stroke survivors

Conditions: Stroke

Summary: the axem home study is a randomized open label trial analyzing the safety and feasibility of coupling the axem home prototype device with exercise to improve motor recovery following a stroke.

the axem home study is a randomized, open label, phase i clinical trial evaluating the safety and feasibility of coupling feedback to participants on their levels of sensorimotor brain activity (via the axem home prototype device) with exercise rehabilitation. 15 participants will be enrolled in each arm of the study. both groups will participate in an exercise program, but only one group (the intervention group) will receive the axem home prototype device. study participants will be evaluated at baseline, after 3 weeks, and after 6 weeks (upon the completion of their time in the early supported discharge program). evaluators will be blinded as to which group participants are in. the study is constructed with randomization to remove selection and allocation biases.

Eligibility criteria:
inclusion criteria: * accepted into the calgary stroke program's early supported discharge program for stroke survivors * aged 18 or older * visual acuity better than 20/50 in both eyes * able to give consent * clinician reported upper-extremity movement deficit exclusion criteria: * score ≥15 on the phq-9 * score \<10 on the moca or \<20 on the casp * inclusion in another interventional trial * have open wounds on their scalp

Keywords: rehabilitation neurofeedback functional near-infrared spectroscopy neuroergonomics motor cortex gamification
narrow-band imaging, autofluorescence imaging and gastroesophageal reflux disease

Conditions: Gastroesophageal Reflux Disease

Summary: aim of this study is to compare the efficacy of narrow band imaging (nbi) and autofluorescence imaging (afi) to distinguish subtle mucosal change related to acid reflux that is not visible in standard white light imaging (wli) endoscopy, and help indicating the diagnosis of gastroesophageal reflux disease (gerd).

gerd is a common condition that develops when the reflux of gastric and/or duodenal contents causes troublesome symptoms with or without mucosal damage or complications. despite the high prevalence of gerd in the general population, up to 60% of patients with reflux symptoms is insufficiently characterized as having normal endoscopic finding based on standard wli endoscopy: non-erosive reflux diseases (nerd). nbi is an optical-digital imaging technology that uses two specific narrow-banded shot wavelength lights (400-430 nm and 525-555 nm) instead of broad band white light. the nbi contrasts surface structure and vascular architecture of the superficial mucosa and facilitates evaluation of indistinct mucosal morphology. afi produces real-time computed images of endoscopically detected autofluorescence emitted from endogenous fluorophores in the digestive tract (collagen, nicotinamide, adenine dinucleotide, flavin, and porphyrins) caused by light excitation. the afi can identify lesions due to differences in tissue fluorescence properties that are not detectable by standard wli. hence, our hypothesis is that new endoscopic imaging i.e. nbi and afi would help to identify subtle mucosal change which indicates the diagnosis of gerd

Eligibility criteria:
1. inclusion criteria * gerd symptom: heartburn or regurgitation (either one) at least 2 days a week * presence of symptom for longer than 1 month before screening * provision of written informed consent 2. exclusion criteria: * any known esophageal disease or disorder, other than reflux esophagitis * active or healing gastroduodenal ulcer (except scars) * history of esophageal or gastric surgery. * clinically significant heart, lung, liver or kidney disease * allergy to proton-pump inhibitor * pregnancy

Keywords: gastroesophageal reflux; endoscopy; esophageal ph monitoring; narrow band imaging; autofluorescence imaging; white light imaging;
target volume delineation after nact in la-npcarcinoma patients treated with nact+ ccrt

Conditions: Nasopharyngeal Carcinoma

Summary: the gross tumor volumes of the primary site and the neck nodes (gtvnx and gtvnd) could be delineated according to the post-nact tumor position and receive radical radiation dose, while the tumor disappear after nact could be encompassed in the first clinical target volume (ctv1) and receive high preventive radiation dose. through this method,it is more likely to achieve the ultimate goal that maximize the chance of cure while minimize the injury of surrounding normal tissues, maintaining organ function and life quality. therefore, this stage ii clinical trial was designed to study the prognosis and locoregional failure patterns of this target volume delineation method in la-npc treated with nact plus ccrt.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed npc; 2. no evidence of distant metastasis; 3. no previous treatment for npc; 4. stages iii-ivb disease according to the staging system of the 6th ajcc/uicc; 5. adequate liver, renal and bone marrow function; 6. karnofsky performance status (kps) ≥80 scores. exclusion criteria: 1. fine-needle aspiration biopsy, incisional or excisional biopsy of neck lymph node, or neck dissection prior nact; 2. disease progression during nact; 3. presence of distant metastasis; 4. pregnancy or lactation; 5. previous malignancy or other concomitant malignant disease.

Keywords: neoadjuvant chemotherapy intensity-modulated radiation therapy target volume delineation locoregional failure pattern nasopharyngeal carcinoma
intravenous paracetamol for postoperative pain

Conditions: Pain, Postoperative; Recovery of Function; Child

Summary: the purpose of this study is to define if intravenous paracetamol may improve analgesia and outcome in pediatric surgical patients treated with non-steroidal anti-inflammatory drugs (nsaids) postoperatively. hypothesis: intravenous paracetamol in a dose 60 mg/kg/24 h iv, given in addition to iv ketoprofen (4,5 mg/kg/24h), improves analgesia and physical recovery in children and adolescents following surgery.

patients aged 1-18 years undergoing general, plastic or orthopedic surgery with expected moderate to severe pain at least for 24 hours postoperatively, who meet inclusion criteria and does not meet exclusion criteria, are enrolled. at the end of surgical procedure, at skin closure, all patients are given 1,5 mg/kg intravenous ketoprofen and repeated every 8 hours up till 4,5 mg/kg/24 h. patients in paracetamol group are additionally given the first dose of iv paracetamol 20 mg/kg and repeated 6 and 20 hours postoperatively up till 60 mg/kg/24 h. patients in the placebo group are given 0.9% sodium chloride 2 ml/kg iv and repeated 6 and 20 hours postoperatively. after surgery optional rescue analgesia is given on patient request: either tramadol in a dose of 2 mg/kg (up till 4 mg/kg/24h), either patient-controlled analgesia (pca) with morphine, as indicated according to the standard of care. patients are evaluated up till 24 hours postoperatively. after that patients are followed up as long as indicated per standard of care.

Eligibility criteria:
inclusion criteria: * patients 1-18 years of age, undergoing general, plastic or orthopedic surgery with expected median to severe pain postoperatively. * physical status of the patient corresponding to american society of anesthesiologists (asa) class 1 or 2 * signed written informed consent by parents/official caregivers. exclusion criteria: * allergy to paracetamol, ketoprofen, tramadol, morphine or any nsaid * oncologic disease * central nervous system disease * renal dysfunction * hepatic dysfunction * bronchial asthma * ulcer(s) in gastrointestinal system * hemorrhagic diathesis * chronic use of nsaids * chronic use of opioids * chronic use of anticoagulants * female patient is known to be pregnant

Keywords: pain, postoperative paracetamol administration, intravenous anti-inflammatory agents, non-steroidal child adolescent
dead space in mechanical ventilation with constant expiratory flow

Conditions: Mechanical Ventilation; Artificial Respiration

Summary: conventional continuous mandatory mechanical ventilation relies on the passive recoil of the chest wall for expiration. this results in an exponentially decreasing expiratory flow. flow controlled ventilation (fcv), a new ventilation mode with constant, continuous, controlled expiratory flow, has recently become clinically available and is increasingly being adopted for complex mechanical ventilation during surgery. in both clinical and pre-clinical settings, an improvement in ventilation (co2 clearance) has been observed during fcv compared to conventional ventilation. recently, schranc et al. compared flow-controlled ventilation with pressure-regulated volume control in both double lung ventilation and one-lung ventilation in pigs. they report differences in dead space ventilation that may explain the improved co2 clearance, although their study was not designed to compare dead space ventilation within the group of double lung ventilation. dead space ventilation, or "wasted ventilation", is the ventilation of hypoperfused lung zones, and is clinically relevant, as it is a strong predictor of mortality in patients with the acute respiratory distress syndrome (ards) and is correlated with higher airway driving pressures which are thought to be injurious to the lung (lung stress). this trial aims to study the difference in dead space ventilation between conventional mechanical ventilation in volume-controlled mode and flow controlled-ventilation.


Eligibility criteria:
inclusion criteria: * adults \[18-70\] yrs * general anaesthesia for elective surgery * arterial line, central venous line and endotracheal tube as part of standard of care * expected duration of controlled mechanical ventilation ≥ 60 minutes * supine position (0±10°) exclusion criteria: * one lung ventilation * known pregnancy * increased intra-abdominal pressure (pneumoperitoneum or obesity (bmi \> 30kg/m2)) * copd gold iv or home oxygen dependence * cardiac pacemaker, implantable cardioverter-defibrillator (icd) or thoracic neurostimulator * skin lesions (e.g. injury, inflammation) at the level where the electrical impedance tomography (eit) band is to be applied * clinical signs of raised intracranial pressure * potential interference with the surgery due to the setup of the study instruments. * patient refusal to participate
gemcitabine with or without ci-994 in treating patients with advanced non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. it is not yet known whether gemcitabine plus ci-994 is more effective than gemcitabine alone for non-small cell lung cancer. purpose: randomized phase iii trial to compare the effectiveness of gemcitabine with or without ci-994 in treating patients who have advanced non-small cell lung cancer.

objectives: i. determine the efficacy and safety of gemcitabine with or without ci-994 in patients with advanced non-small cell lung cancer. outline: this is a randomized, double blind, placebo controlled, multicenter study. patients are stratified according to performance status and are randomized to one of two treatment arms. arm i: patients receive ci-994 orally on days 1-21 and gemcitabine iv over 30 minutes on days 1, 8, and 15. arm ii: patients receive placebo capsules orally on days 1-21 and gemcitabine as in arm i. treatment repeats every 28 days as long as medically appropriate (absence of disease progression or unacceptable toxicity). projected accrual: a total of 176 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed recurrent, locally advanced, or metastatic, unresectable non-small cell lung cancer failed or relapsed after one prior platinum containing regimen (cisplatin or carboplatin) as first line therapy prior brain metastases allowed if resection and/or radiotherapy completed, no worsening of cns symptoms, and at least 1 month since prior corticosteroids patient characteristics: age: 18 and over performance status: karnofsky 70-100% life expectancy: greater than 12 weeks hematopoietic: absolute neutrophil count at least 2,000/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) ast or alt no greater than 3 times uln (no greater than 5 times uln in patients with liver metastases) renal: creatinine clearance at least 50 ml/min other: able to swallow intact study capsules no active infection no life threatening illness (other than tumor) no prior malignancy within the past 5 years except well controlled nonmelanomatous skin cancer not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy no more than one prior regimen of chemotherapy no prior gemcitabine no prior ci-994 at least 4 weeks since prior maintenance or consolidation therapy (e.g., matrix metalloprotein inhibitors) endocrine therapy: see disease characteristics radiotherapy: see disease characteristics at least 4 weeks since prior radiotherapy to primary site surgery: not specified

Keywords: recurrent non-small cell lung cancer stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
impact of rotavirus vaccination on hospital pressures at a large paediatric hospital in the uk: an ecological study

Conditions: Gastroenteritis

Summary: the impact of rotavirus vaccination on the burden of disease has been well documented. however, the anticipated reduction in hospital pressures has yet to be described. this study will provide quantitative measures of hospital pressure prior to and post vaccine introduction, provide a template for future hospital pressures studies related to vaccine introduction and provide measures which could be used in an economic evaluation.


Eligibility criteria:
inclusion criteria: * all children aged ≤15 years being hospitalised (with overnight stay or day clinic) for whatever reason during the study period exclusion criteria: * none
popliteal artery of treatment with balloon angioplasty vs. supera veritas peripheral stent system

Conditions: Peripheral Vascular Disease

Summary: unblinded, randomized, balanced trial comparing 12 month target lesion patency rates of the idev supera veritas peripheral stent system to pta in the treatment of obstructive atherosclerotic popliteal artery disease.


Eligibility criteria:
inclusion criteria: * subject has lifestyle limiting claudication or rest pain or at least a single de novo or restenotic popliteal artery lesion. exclusion criteria: * intervention distal to the target lesion is required at the time of the index procedure or within 30 days after the index procedure.
digitalization playful module of motor function measure assessment for children with neuromuscular disorders, mfm-play pilot study.

Conditions: Neuromuscular Diseases

Summary: the motor function measure (mfm) is a functional rating scale consisting of 32 items assessing motor functional abilities in a person with neuromuscular disease. by exploring the potential of digital technologies applied to mfm, for each item completion we want to create digital animations containing different playful and informative scenarios. this digital evolution aims to standardize assessment on the therapist's side, but also to improve acceptance of scale and patient participation. despite the modification of the mfm completion by digital animation, the study hypothesis is that the metrological qualities of the scale are retained. through the mfm-play pilot study, the objective is to test 5 items of the mfm-play scale before carrying out a validation study of the total mfm-play.


Eligibility criteria:
inclusion criteria: * girls and boys with a neuromuscular disease * aged 6 to 11 years old * with parental assent exclusion criteria: * patients participating to a therapeutic trial * patients without compartmental capacities to participate normally to the mfm.

Keywords: neuromuscular diseases